Is the price fair?
What RCUS's price assumes
Arcus Biosciences, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 11.5× revenue.
11.5
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 5.17
Price / book · as of 2026-Q1
- EV / sales
- 11.1
EV / sales
Details›
- Price / book2026-Q1
- 5.17
- EV / EBIToperating margin −415%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 11.1
- Market capitalisation
- $3.06B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.